Erratum: Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomized controlled trial (Journal of Clinical Oncology (2015) 33, (2279-2287) DOI: 10.1200/JCO.2014.60.0734);Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomized controlled trial

Journal of Clinical Oncology

Volumn 33, Issue 20, 2015, Pages 2279-2287

  Bielack, Stefan S ^a   Werner, Mathias ^b   Tunn, Per Ulf ^c   Helmke, Knut ^d   Jürgens, Heribert ^e   Calaminus, Gabriele ^e   Gerss, Joachim ^e   Butterfass Bahloul, Trude ^e   Reichardt, Peter ^f   Smeland, Sigbjørn ^g   Hall, Kirsten Sundby ^g,h   Whelan, Jeremy S ⁱ   Jovic, Gordana ^j   Hook, Jane M ^j   Sydes, Matthew R ^j   Seddon, Beatrice ^k   Michelagnoli, Maria ^k   Brennan, Bernadette ^l   Picton, Susan ^m   Marina, Neyssa ⁿ   Deffenbaugh, Claudia ^o   Krailo, Mark D ^p   Gebhardt, Mark ^q,r   Goorin, Allen ^q   Teot, Lisa A ^r   Pápai, Zsuzsanna ^s   Meyer, James ^t   Nadel, Helen ^u   Bernstein, Mark ^v   Randall, R Lor ^w   Nagarajan, Rajaram ^x   Letson, G Douglas ^y   Baumhoer, Daniel ^z   Kühne, Thomas ^aa   Kager, Leo ^ab   Windhager, Reinhard ^ac   Lau, Ching C ^ad   Gelderblom, Hans ^ae   Hogendoorn, Pancras C W ^ae   Hoogerbrugge, Peter M ^af   Van Den Berg, Henk ^ag   Meyers, Paul ^ah   Morris, Carol ^ah   Gorlick, Richard ^ai   Eriksson, Mikael ^aj   Schomberg, Paula ^ak   Böhling, Tom ^al   Renard, Marleen ^am   Dhooge, Catharina ^an   more..

^a OLGAHOSPITAL   (Germany)

^b HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

^d Altonaer Kinderkrankenhaus   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f Klinik für Interdisziplinäre Onkologie   (Germany)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^l ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^m UNIVERSITY OF LEEDS   (United Kingdom)

ⁿ STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^o LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^p CHILDREN S ONCOLOGY GROUP   (United States)

^q DANA FARBER CANCER INSTITUTE   (United States)

^r BOSTON CHILDREN S HOSPITAL   (United States)

^s NATIONAL MEDICAL CENTER   (Hungary)

^t UNIVERSITY OF PENNSYLVANIA   (United States)

^u UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^v DALHOUSIE UNIVERSITY   (Canada)

^w UNIVERSITY OF UTAH   (United States)

^x CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^y H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^z UNIVERSITY HOSPITAL BASEL   (Switzerland)

^aa UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^ab St Anna's Children Hospital   (Switzerland)

^ac MEDICAL UNIVERSITY OF VIENNA   (Austria)

^ad BAYLOR COLLEGE OF MEDICINE   (United States)

^ae LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^af RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^ag ACADEMIC MEDICAL CENTER   (Netherlands)

^ah MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^ai MONTEFIORE MEDICAL CENTER   (United States)

^aj LUND UNIVERSITY HOSPITAL   (Sweden)

^ak MAYO CLINIC   (United States)

^al UNIVERSITY OF HELSINKI   (Finland)

^am UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^an GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; PEGINTERFERON ALPHA2B; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; CANCER GRADING; CHILD; CHILL; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HAZARD RATIO; HEADACHE; HEART ARRHYTHMIA; HUMAN; INDUCTION CHEMOTHERAPY; JOINT EFFUSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIMB PAIN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGOR; THYROID DISEASE; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE; VOMITING; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; ASIA; AUSTRALIA; BONE NEOPLASMS; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; EUROPE; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; NEOADJUVANT THERAPY; NORTH AMERICA; OSTEOTOMY; PATHOLOGY; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIA; AUSTRALIA; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; EUROPE; FEMALE; HUMANS; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; NEOADJUVANT THERAPY; NEOPLASM GRADING; NORTH AMERICA; OSTEOSARCOMA; OSTEOTOMY; POLYETHYLENE GLYCOLS; PROPORTIONAL HAZARDS MODELS; RECOMBINANT PROTEINS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84941276779     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.70.9923     Document Type: Erratum

References (35)

1. Gorlick R, Bielack S, Teot L, et al: Osteosarcoma: Biology, diagnosis, treatment, and remaining challenges, in Pizzo P, Poplack D (eds): Principles and Practice of Pediatric Oncology (ed 6). Philadelphia, PA, Lippincott Williams and Wilkins, 2011, pp 1015-1044
2. Mirabello L, Troisi RJ, Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:1531-1543, 2009
3. Stiller CA, Bielack SS, Jundt G, et al: Bone tumours in European children and adolescents, 1978-1997: Report from the Automated Childhood Cancer Information System project. Eur J Cancer 42:2124-2135, 2006
4. Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776-790, 2002
5. Bielack S, Jürgens H, Jundt G, et al: Osteosarcoma: The COSS experience. Cancer Treat Res 152:289-308, 2009
6. Bruland ØS, Bauer H, Alvegaard T, et al: Treatment of osteosarcoma: The Scandinavian Sarcoma Group experience, in Jaffe N, Bruland OS, Stefan B (eds): Pediatric and Adolescent Osteosarcoma: Series - Cancer Treatment and Research. New York, NY, Springer, 2009, pp 309-318
7. Meyers PA, Schwartz CL, Krailo M, et al: Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004-2011, 2005
8. Meyers PA, Schwartz CL, Krailo MD, et al: Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the Children's Oncology Group. J Clin Oncol 26:633-638, 2008
9. Whelan JS, Jinks RC, McTiernan A, et al: Survival from high-grade localised extremity osteosarcoma: Combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann Oncol 23:1607-1616, 2012
10. Marina N, Bielack S, Whelan J, et al: International collaboration is feasible in trials for rare conditions: The EURAMOS experience. Cancer Treat Res 152:339-353, 2009
11. Whelan JS, Bielack SS, Marina N, et al: EURAMOS-1, an international randomised study for osteosarcoma: Results from pre-randomisation treatment. Ann Oncol 26:407-414, 2015
12. Smeland S, Bruland OS, Hjorth L, et al: Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years. Acta Orthop 82:211- 216, 2011
13. Whelan J, Patterson D, Perisoglou M, et al: The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer 54:350-354, 2010
14. Pui CH, Mullighan CG, Evans WE, et al: Pediatric acute lymphoblastic leukemia: Where are we going and how do we get there? Blood 120:1165- 1174, 2012
15. Ray-Coquard I, Le Cesne A: A role for maintenance therapy in managing sarcoma. Cancer Treat Rev 38:368-378, 2012
16. Bukowski RM, Tendler C, Cutler D, et al: Treating cancer with PEG intron: Pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 95:389-396, 2002
17. Fritz E, Ludwig H: Interferon-alpha treatment in multiple myeloma: Meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 11:1427-1436, 2000
18. Kirkwood JM, Butterfield LH, Tarhini AA, et al: Immunotherapy of cancer in 2012. CA Cancer J Clin 62:309-335, 2012
19. Tarhini AA, Kirkwood JM: How much of a good thing? What duration for interferon alfa-2b adjuvant therapy? J Clin Oncol 30:3773-3776, 2012
20. Kubo T, Shimose S, Matsuo T, et al: Interferonalpha/ beta receptor as a prognostic marker in osteosarcoma. J Bone Joint Surg Am 93:519-526, 2011
21. Müller CR, Smeland S, Bauer HC, et al: Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: Long term results of the Karolinska Hospital series. Acta Oncol 44:475-480, 2005
22. Michaud AP, Bauman NM, Burke DK, et al: Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope 114:1231-1236, 2004
23. National Cancer Institute: Common Terminology Criteria for Adverse Events (version 3.0). http:// ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf
24. George SL, Desu MM: Planning the size and duration of a clinical trial studying the time to some critical event. J Chron Dis 27:15-24, 1974
25. Haybittle JL: Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 44:793-797, 1971
26. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I. Introduction and design. Br J Cancer 34:585-612, 1976
27. Le Deley MC, Guinebretière JM, Gentet JC, et al: SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 43:752-761, 2007
28. Daud A, Soon C, Dummer R, et al: Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opin Biol Ther 12:1087-1099, 2012
29. van Dalen EC, van der Pal HJ, Caron HN, et al: Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 4:CD005008, 2009
30. Jakacki RI, Dombi E, Potter DM, et al: Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas. Neurology 76: 265-272, 2011
31. Bosly A, Grigg A, Holte H, et al: A randomized study of interferon alpha-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma. Oncologist 18:1189, 2013
32. Sondak VK, Kudchadkar R: Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role? Oncologist 17:1223- 1224, 2012
33. Jia SF, An T, Worth L, et al: Interferon-alpha enhances the sensitivity of human osteosarcoma cells to etoposide. J Interferon Cytokine Res 19:617-624, 1999
34. Eggermont AM, Suciu S, Testori A, et al: Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 30:3810-3818, 2012
35. Fletcher CDM, Unni KK, Mertens F (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France, IARC Press, 2002